(MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115823
Author :
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
